Since we had previously developed a high-resolution melting (HRM) assay to detect somatic KRAS, BRAF, and EGFR mutations in tumor samples from patients considered for EGFR-targeted therapies (Borràs et al., 2011), we included the detection of the DPYD c.1905+1G>A mutation in this screening test. This evidence concerns the gene BRAF and neoplasm.